By Mohammed Juma
Kenya in a major milestone for public health, has signed an agreement with global pharmaceutical company Pfizer to reduce the cost of essential medicines by up to 60% through its Ministry of Health.
The partnership was unveiled on Monday during an event in Nairobi, presided over by Principal Secretary for Medical Services Dr. Ouma Oluga and Pfizer Global President for Emerging Markets, Mr. Nick Lagunowich.
The deal aims to improve access to treatment for non-communicable and infectious diseases, including diabetes, cancer and bacterial infections—conditions that continue to strain Kenya’s healthcare system.
The reduced pricing will primarily benefit patients in public health facilities, helping bridge the gap in access to quality medication, especially in underserved regions.
“This partnership is not just about cheaper medicine—it is about giving hope and dignity to every Kenyan who walks into a health facility,” said Dr. Ouma Oluga during the launch.
“It is a bold step toward equitable healthcare, especially for those who have had to choose between medicine and meals,” he added.
Pfizer’s Nick Lagunowich noted that the agreement is part of the company’s broader commitment to health equity in emerging markets.
“We believe that access to medicine should not be determined by geography or income. This initiative reflects our shared vision with Kenya’s Ministry of Health to ensure no one is left behind,” he said.
The partnership will initially focus on high-burden diseases, with potential expansion based on national health priorities.
The Ministry of Health confirmed that implementation will begin immediately, with the first batch of discounted drugs expected to reach select health facilities within the next few months.
The move marks a significant stride in Kenya’s journey toward universal health coverage, aligning with its commitment to make healthcare more affordable and accessible for all.